Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 30,000 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 30,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average price of $16.30 per share, with a total value of $489,000.00. Following the completion of the acquisition, the chief executive officer directly owned 346,155 shares in the company, valued at $5,642,326.50. The trade was a 9.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Zenas BioPharma Price Performance

Shares of Zenas BioPharma stock opened at $16.08 on Friday. The company’s fifty day simple moving average is $34.94 and its two-hundred day simple moving average is $24.01. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $44.60. The firm has a market cap of $863.17 million, a PE ratio of -2.27 and a beta of -1.45. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Institutional Trading of Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares in the last quarter. Millennium Management LLC bought a new stake in Zenas BioPharma during the third quarter worth about $1,595,000. Bank of America Corp DE grew its holdings in Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares during the period. Alliancebernstein L.P. grew its holdings in Zenas BioPharma by 12.2% in the third quarter. Alliancebernstein L.P. now owns 18,350 shares of the company’s stock worth $407,000 after purchasing an additional 1,990 shares during the period. Finally, Creative Planning bought a new position in shares of Zenas BioPharma during the third quarter valued at approximately $264,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ZBIO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Wedbush reissued an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Citigroup upped their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Finally, Evercore ISI assumed coverage on shares of Zenas BioPharma in a research note on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon O. Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (aggregate ≈ $1.63M), increasing his stake to 366,155 shares — a strong insider-buy signal that typically supports near-term buying interest. Read More.
• Positive Sentiment: Brokerages have assigned a consensus rating of “Moderate Buy” for ZBIO, which can attract institutional and retail demand if the view is publicized and reinforced. Read More.
• Neutral Sentiment: Multiple SEC filings disclose the CEO purchases (detailed trade dates and average prices), confirming the insider transactions are official, transparent, and recently reported. Read More.
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into Zenas BioPharma, which creates litigation risk and may increase volatility or prompt selling pressure until details clarify. Read More.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.